AVITA Medical’s (RCEL) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital reaffirmed their buy rating on shares of AVITA Medical (NASDAQ:RCEL – Free Report) in a report issued on Friday,Benzinga reports. The firm currently has a $25.00 price objective on the stock. Several other research analysts also recently weighed in on the company. Piper Sandler reiterated a “neutral” rating and set a $12.00 […]
D. Boral Capital reaffirmed their buy rating on shares of AVITA Medical (NASDAQ:RCEL – Free Report) in a report issued on Friday,Benzinga reports. The firm currently has a $25.00 price objective on the stock. Several other research analysts also recently weighed in on the company. Piper Sandler reiterated a “neutral” rating and set a $12.00 […]
